---
title: "688321.SH (688321.SH) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688321.SH/news.md"
symbol: "688321.SH"
name: "688321.SH"
parent: "https://longbridge.com/en/quote/688321.SH.md"
datetime: "2026-05-21T02:54:01.075Z"
locales:
  - [en](https://longbridge.com/en/quote/688321.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688321.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688321.SH/news.md)
---

# 688321.SH (688321.SH) — Related News

### [Chipscreen: The inquiry transfer price is 25.68 yuan/share](https://longbridge.com/en/news/286736795.md)
*2026-05-18T08:15:12.000Z*
> Chipscreen announced that, based on the inquiry subscription situation on May 18, 2026, the preliminary determined inqui

### [Chipscreen: Shareholders plan to inquire about the transfer of 5% of the company's shares](https://longbridge.com/en/news/286551808.md)
*2026-05-15T10:51:45.000Z*
> Chipscreen announced that shareholders plan to transfer 5% of the company's shares, totaling 22.1404 million shares. The

### [Chipscreen's core product patents face partial invalidation: last year's revenue accounted for over 60%, the company claims it will not adversely affect production and operations](https://longbridge.com/en/news/285804729.md)
*2026-05-09T08:28:12.000Z*
> Chipscreen (SH688321) announced that the patent for its core product, Sidabenamine, has been declared partially invalid,

### [Chipscreen received the "Review Decision on Invalidity Declaration Request" from the National Intellectual Property Administration](https://longbridge.com/en/news/285703392.md)
*2026-05-08T10:09:03.000Z*
> Chipscreen recently received the "Review Decision on Invalidity Declaration Request" from the National Intellectual Prop

### [Chipscreen: Net profit in the first quarter was 28.2719 million yuan, a year-on-year increase of 247.60%](https://longbridge.com/en/news/284527237.md)
*2026-04-29T08:53:21.000Z*
> Chipscreen announced that in the first quarter of 2026, operating revenue was 257 million yuan, a year-on-year increase 

### [Hepatology: In the fight against liver "metabolic fire," the team led by You Hong from Capital Medical University discovered that sodium siglitazone demonstrated multi-target efficacy in Phase II clinical trials, significantly reducing liver fat](https://longbridge.com/en/news/284493529.md)
*2026-04-29T04:45:40.000Z*
> The research team led by You Hong from Capital Medical University published a study in Hepatology, evaluating the effica

### [Adv Sci: Precision "transformation" of tumor accomplices! A team led by Chen Tong from Fudan University reveals new regulatory targets of macrophages in lymphoma and constructs an intelligent delivery system for efficient intervention](https://longbridge.com/en/news/281993370.md)
*2026-04-08T07:25:19.000Z*
> Researchers Chen Tong from Fudan University and Tong Yin from Shanghai Jiao Tong University published a study in *Advanc

### [Chipscreen: As of the end of March, a total of 67,025 shares have been repurchased at a cost of nearly 2 million yuan](https://longbridge.com/en/news/281354150.md)
*2026-04-01T11:07:16.000Z*
> Chipscreen plans to repurchase shares through a buyback scheme with an amount ranging from 80 million to 120 million yua